{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T13:10:44Z","timestamp":1767964244370,"version":"3.49.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Syst Biol"],"published-print":{"date-parts":[[2013,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Cancer is a broad group of genetic diseases which account for millions of deaths worldwide each year. Cancers are classified by various clinical, pathological and molecular methods, but even within a well-characterized disease, there is a significant inter-patient variability in survival, response to treatment, and other parameters. Especially in molecular level, tumours of the same category can appear significantly dissimilar due to complex combinations of genetic aberrations leading to a similar malignancy. We extended the current classification methods by studying tumour heterogeneity at pathway level.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We computed the rate of alterations in 1994 pathways and 2210 tumours consisting of eight different cancers. Using gene set enrichment analysis, each sample was computed a pathway aberration profile that reflected its molecular state. The profiles were analysed together to infer the characteristic aberration rates for each pathway within each cancer. Subgroups of tumours defined by similar pathway aberrations were identified using clustering analyses. The pathway aberration and gene expression profiles of the subgroups were consecutively compared across all eight cancer types to search for similar tumours crossing the standard classification.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>We identified pathways and processes that were common to all cancers as well as traits that are unique to a cancer type or closely related cancers. Studying the gene expression patterns within the pathway context suggested potential alteration mechanisms. Clustering analysis revealed five clinically relevant subgroups of tumours in four cancers that exhibited significant differences in survival compared to others. The cross-cancer analysis of the subgroups resulted in the identification of tumours that shared potentially significant alterations.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>This study represents the first effort to extend the molecular characterizations towards pathway level descriptions across the family of cancers. In addition to providing a proof-of-concept for single sample pathway aberration analysis in this context, we present a comprehensive pathway aberration dataset that can be used to study pathway aberration patterns within or across cancers. Significant similarities between subgroups of different cancers on pathway and gene expression levels provide interesting hypotheses for understanding variable drug response, or transferring treatments across diseases by identifying common druggable pathways or genes, for example.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1752-0509-7-s1-s1","type":"journal-article","created":{"date-parts":[[2019,12,11]],"date-time":"2019-12-11T02:04:19Z","timestamp":1576029859000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Characterization of aberrant pathways across human cancers"],"prefix":"10.1186","volume":"7","author":[{"given":"Antti","family":"Ylip\u00e4\u00e4","sequence":"first","affiliation":[]},{"given":"Olli","family":"Yli-Harja","sequence":"additional","affiliation":[]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[]},{"given":"Matti","family":"Nykter","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2013,8,12]]},"reference":[{"issue":"8","key":"1124_CR1","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/nm1087","volume":"10","author":"B Vogelstein","year":"2004","unstructured":"Vogelstein B, Kinzler KW: Cancer genes and the pathways they control. Nat Med. 2004, 10 (8): 789-99. 10.1038\/nm1087.","journal-title":"Nat Med"},{"issue":"5","key":"1124_CR2","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell. 2011, 144 (5): 646-74. 10.1016\/j.cell.2011.02.013.","journal-title":"Cell"},{"issue":"6810","key":"1124_CR3","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/35042675","volume":"408","author":"B Vogelstein","year":"2000","unstructured":"Vogelstein B, Lane D, Levine AJ: Surfing the p53 network. Nature. 2000, 408 (6810): 307-10. 10.1038\/35042675.","journal-title":"Nature"},{"issue":"5","key":"1124_CR4","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/87872","volume":"7","author":"J Bange","year":"2001","unstructured":"Bange J, Zwick E, Ullrich A: Molecular targets for breast cancer therapy and prevention. Nat Med. 2001, 7 (5): 548-52. 10.1038\/87872.","journal-title":"Nat Med"},{"issue":"6","key":"1124_CR5","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1200\/JCO.20.6.1692","volume":"20","author":"MC Heinrich","year":"2002","unstructured":"Heinrich MC, Blanke CD, Druker BJ, Corless CL: Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol. 2002, 20 (6): 1692-703. 10.1200\/JCO.20.6.1692.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1124_CR6","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/path.2645","volume":"220","author":"DW Bell","year":"2010","unstructured":"Bell DW: Our changing view of the genomic landscape of cancer. J Pathol. 2010, 220 (2): 231-43.","journal-title":"J Pathol"},{"issue":"7283","key":"1124_CR7","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/nature08822","volume":"463","author":"R Beroukhim","year":"2010","unstructured":"Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M, Mc Henry KT, Pinchback RM, Ligon AH, Cho YJ, Haery L, Greulich H, Reich M, Winckler W, Lawrence MS, Weir BA, Tanaka KE, Chiang DY, Bass AJ, Loo A, Hoffman C, Prensner J, Liefeld T, Gao Q, Yecies D, Signoretti S, Maher E, Kaye FJ, Sasaki H, Tepper JE, Fletcher JA, Tabernero J, Baselga J, Tsao MS, Demichelis F, Rubin MA, Janne PA, Daly MJ, Nucera C, Levine RL, Ebert BL, Gabriel S, Rustgi AK, Antonescu CR, Ladanyi M, Letai A, Garraway LA, Loda M, Beer DG, True LD, Okamoto A, Pomeroy SL, Singer S, Golub TR, Lander ES, Getz G, Sellers WR, Meyerson M: The landscape of somatic copy-number alteration across human cancers. Nature. 2010, 463 (7283): 899-905. 10.1038\/nature08822.","journal-title":"Nature"},{"key":"1124_CR8","first-page":"171","volume-title":"Urologic Pathology: The Prostate","author":"DF Gleason","year":"1977","unstructured":"Gleason DF: The Veteran's Administration Cooperative Urologic Research Group: histologic grading and clinical staging of prostatic carcinoma. Urologic Pathology: The Prostate. Edited by: Tannenbaum M. 1977, Philadelphia: Lea and Febiger, 171-198."},{"issue":"2","key":"1124_CR9","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00401-007-0243-4","volume":"114","author":"DN Louis","year":"2007","unstructured":"Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007, 114 (2): 97-109. 10.1007\/s00401-007-0243-4.","journal-title":"Acta Neuropathol"},{"issue":"8","key":"1124_CR10","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/ng.619","volume":"42","author":"J Barretina","year":"2010","unstructured":"Barretina J, Taylor BS, Banerji S, Ramos AH, Lagos-Quintana M, Decarolis PL, Shah K, Socci ND, Weir BA, Ho A, Chiang DY, Reva B, Mermel CH, Getz G, Antipin Y, Beroukhim R, Major JE, Hatton C, Nicoletti R, Hanna M, Sharpe T, Fennell TJ, Cibulskis K, Onofrio RC, Saito T, Shukla N, Lau C, Nelander S, Silver SJ, Sougnez C, et al: Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Anal Nat Genet. 2010, 42 (8): 715-21. 10.1038\/ng.619.","journal-title":"Anal Nat Genet"},{"issue":"1","key":"1124_CR11","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ccr.2009.12.020","volume":"17","author":"RG Verhaak","year":"2010","unstructured":"Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O'Kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennan C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M, Getz G, Perou CM, Hayes DN, Cancer Genome Atlas Research Network: Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010, 17 (1): 98-110. 10.1016\/j.ccr.2009.12.020.","journal-title":"Cancer Cell"},{"issue":"7216","key":"1124_CR12","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/nature07385","volume":"455","author":"Cancer Genome Atlas Research Network","year":"2008","unstructured":"Cancer Genome Atlas Research Network: Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008, 455 (7216): 1061-8. 10.1038\/nature07385.","journal-title":"Nature"},{"issue":"7353","key":"1124_CR13","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nature10166","volume":"474","author":"Cancer Genome Atlas Research Network","year":"2011","unstructured":"Cancer Genome Atlas Research Network: Integrated genomic analyses of ovarian carcinoma. Nature. 2011, 474 (7353): 609-15. 10.1038\/nature10166.","journal-title":"Nature"},{"issue":"7418","key":"1124_CR14","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nature11412","volume":"490","author":"Cancer Genome Atlas Network","year":"2012","unstructured":"Cancer Genome Atlas Network: Comprehensive molecular portraits of human breast tumours. Nature. 2012, 490 (7418): 61-70. 10.1038\/nature11412.","journal-title":"Nature"},{"issue":"7407","key":"1124_CR15","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nature11252","volume":"487","author":"Cancer Genome Atlas Network","year":"2012","unstructured":"Cancer Genome Atlas Network: Comprehensive molecular portraits of human colon and rectal cancer. Nature. 2012, 487 (7407): 330-7. 10.1038\/nature11252.","journal-title":"Nature"},{"issue":"7417","key":"1124_CR16","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/nature11404","volume":"489","author":"PS Hammerman","year":"2012","unstructured":"Cancer Genome Atlas Research Network, Hammerman PS, Hayes DN, Wilkerson MD, Schultz N, Bose R, Chu A, Collisson EA, Cope L, Creighton CJ, Getz G, Herman JG, Johnson BE, Kucherlapati R, Ladanyi M, Maher CA, Robertson G, Sander C, Shen R, Sinha R, Sivachenko A, Thomas RK, Travis WD, Tsao MS, Weinstein JN, Wigle DA, Baylin SB, Govindan R, Meyerson M: Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012, 489 (7417): 519-25. 10.1038\/nature11404.","journal-title":"Nature"},{"issue":"5","key":"1124_CR17","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.ccr.2010.03.017","volume":"17","author":"H Noushmehr","year":"2010","unstructured":"Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, Pan F, Pelloski CE, Sulman EP, Bhat KP, Verhaak RG, Hoadley KA, Hayes DN, Perou CM, Schmidt HK, Ding L, Wilson RK, Van Den Berg D, Shen H, Bengtsson H, Neuvial P, Cope LM, Buckley J, Herman JG, Baylin SB, Laird PW, Aldape K, Cancer Genome Atlas Research Network: Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 2010, 17 (5): 510-22. 10.1016\/j.ccr.2010.03.017.","journal-title":"Cancer Cell"},{"issue":"4","key":"1124_CR18","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.ccr.2012.08.024","volume":"22","author":"D Sturm","year":"2012","unstructured":"Sturm D, Witt H, Hovestadt V, Khuong-Quang DA, Jones DT, Konermann C, Pfaff E, T\u00f6njes M, Sill M, Bender S, Kool M, Zapatka M, Becker N, Zucknick M, Hielscher T, Liu XY, Fontebasso AM, Ryzhova M, Albrecht S, Jacob K, Wolter M, Ebinger M, Schuhmann MU, van Meter T, Fr\u00fchwald MC, Hauch H, Pekrun A, Radlwimmer B, Niehues T, von Komorowski G: Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell. 2012, 22 (4): 425-37. 10.1016\/j.ccr.2012.08.024.","journal-title":"Cancer Cell"},{"issue":"4","key":"1124_CR19","doi-asserted-by":"publisher","first-page":"e35236","DOI":"10.1371\/journal.pone.0035236","volume":"7","author":"R Shen","year":"2012","unstructured":"Shen R, Mo Q, Schultz N, Seshan VE, Olshen AB, Huse J, Ladanyi M, Sander C: Integrative subtype discovery in glioblastoma using iCluster. PLoS One. 2012, 7 (4): e35236-10.1371\/journal.pone.0035236.","journal-title":"PLoS One"},{"issue":"12","key":"1124_CR20","doi-asserted-by":"publisher","first-page":"i237","DOI":"10.1093\/bioinformatics\/btq182","volume":"26","author":"CJ Vaske","year":"2010","unstructured":"Vaske CJ, Benz SC, Sanborn JZ, Earl D, Szeto C, Zhu J, Haussler D, Stuart JM: Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM. Bioinformatics. 2010, 26 (12): i237-45. 10.1093\/bioinformatics\/btq182.","journal-title":"Bioinformatics"},{"issue":"43","key":"1124_CR21","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP: Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005, 102 (43): 15545-50. 10.1073\/pnas.0506580102.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"1124_CR22","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.ctrv.2011.06.006","volume":"38","author":"G Curigliano","year":"2012","unstructured":"Curigliano G: New drugs for breast cancer subtypes: targeting driver pathways to overcome resistance. Cancer Treat Rev. 2012, 38 (4): 303-10. 10.1016\/j.ctrv.2011.06.006.","journal-title":"Cancer Treat Rev"},{"issue":"7","key":"1124_CR23","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1038\/sj.bjp.0706013","volume":"143","author":"P Jurasz","year":"2004","unstructured":"Jurasz P, Alonso-Escolano D, Radomski MW: Platelet-cancer interactions: mechanisms and pharmacology of tumour cell-induced platelet aggregation. Br J Pharmacol. 2004, 143 (7): 819-826. 10.1038\/sj.bjp.0706013.","journal-title":"Br J Pharmacol"},{"issue":"4","key":"1124_CR24","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/1096-9896(2000)9999:9999<::AID-PATH750>3.0.CO;2-0","volume":"192","author":"GI Murray","year":"2000","unstructured":"Murray GI: The role of cytochrome P450 in tumour development and progression and its potential in therapy. J Pathol. 2000, 192 (4): 419-26. 10.1002\/1096-9896(2000)9999:9999<::AID-PATH750>3.0.CO;2-0.","journal-title":"J Pathol"},{"issue":"9","key":"1124_CR25","first-page":"3246","volume":"9","author":"RH Mathijssen","year":"2003","unstructured":"Mathijssen RH, Marsh S, Karlsson MO, Xie R, Baker SD, Verweij J, Sparreboom A, McLeod HL: Irinotecan pathway genotype analysis to predict pharmacokinetics. Clin Cancer Res. 2003, 9 (9): 3246-53.","journal-title":"Clin Cancer Res"},{"issue":"16","key":"1124_CR26","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1101\/gad.1958410","volume":"24","author":"J Dong","year":"2010","unstructured":"Dong J, Jimi E, Zeiss C, Hayden MS, Ghosh S: Constitutively active NF-kappaB triggers systemic TNFalpha-dependent inflammation and localized TNFalpha-independent inflammatory disease. Genes Dev. 2010, 24 (16): 1709-17. 10.1101\/gad.1958410.","journal-title":"Genes Dev"}],"container-title":["BMC Systems Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1752-0509-7-S1-S1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1752-0509-7-S1-S1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1752-0509-7-S1-S1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T01:04:00Z","timestamp":1630544640000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcsystbiol.biomedcentral.com\/articles\/10.1186\/1752-0509-7-S1-S1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":26,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["1124"],"URL":"https:\/\/doi.org\/10.1186\/1752-0509-7-s1-s1","relation":{},"ISSN":["1752-0509"],"issn-type":[{"value":"1752-0509","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8]]},"assertion":[{"value":"12 August 2013","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"S1"}}